Alemtuzumab

Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research[1][2].

Product Specifications

CAS Number

[216503-57-0]

Product Name Alternative

Campath-IH

UNSPSC

12352203

Target

Apoptosis

Type

Inhibitory Antibodies

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/alemtuzumab.html

Purity

99.81

Solubility

H2O

Smiles

[Alemtuzumab]

Molecular Weight

(146.06 kDa)

References & Citations

[1]Kashani N, et al. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021;12:706278. Published 2021 Oct 28. |[2]Yanping Hu, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009 Oct;128 (2) :260-70.